New Global Coalition Launches to Address the Hidden Threat of RSV in Adults 27-10-2025, 02:17

Subsea7 completion of the acquisition of 187,889,551 shares 14-03-2023, 21:28

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00